SHARE

OFFER: Funding available for COVID-19 research

26th juni 2020

Fondation Air Liquide is looking to fund COVID-19 projects in the respiratory field from reputed Research Institutions in the European Economic Area.

They are able to finance medium-term projects, lasting 12 to 24 month, with a total budget of €100,000 up to €500,000.

The Foundation is able to contribute 30% to 50% of the total budget to the project.

The projects will have to address the following challenges:

  1. Providing a better understanding of COVID-19, in particular:
    • aerial transmission
    • pulmonary impact
    • impact on respiratory function
    • anti-viral strategy development (basic research)
    • epidemiology of the transmission of the virus (in particular by air) allowing better protection of individuals
    • adaptation of respiratory physiology to systemic dysfunctions induced by COVID-19.
  2. Improving respiratory care for severe COVID-19 patients, including:
  • COVID-19 disease aggravating biomarkers and adapted therapeutic strategies
  • efficacy of respiratory protocols in emerging countries in Africa, South America, South Asia and South East.
  1. Improving the long-term management of patients who have had a severe form of COVID-19, by looking at:
  • what extra-hospital treatment protocols should be developed for avoiding specific pulmonary sequelae
  • the impact of healthcare organisation systems on monitoring patients discharged from intensive care and then discharged from hospital

To submit a project, please visit their website.

For more information, please contact
Bruno Leprince-Ringuet

| |
Contact

ASK: Research contributors needed for CON-VICE study

ASK: Research contributors needed for CON-VICE study

University of Luxembourg needs European researchers to get in touch

Find out more

OFFER: Funding available for COVID-19 research

OFFER: Funding available for COVID-19 research

Fondation Air Liquide are looking to fund European projects

Find out more

ASK: Supporting the immunocompromised

ASK: Supporting the immunocompromised

Partners sought to advance neutralising antibody

Find out more